D&D PharmaTech Co.
D&D Pharmatech Inc. engages in the research and development and manufacturing of pharmaceuticals in South Korea. It develops oral peptides, such as MET-002o, MET-224o, MET-097o, DD03, DD07, and DD14 programs for obesity indications in the development phase; injectable peptides, including DD01 for MASH indications; NLY12 and DD15 for obesity indications; and Pegsebrenatide (NLY01) for Parkinson's … Read more
D&D PharmaTech Co. (347850) - Net Assets
Latest net assets as of March 2025: ₩63.92 Billion KRW
Based on the latest financial reports, D&D PharmaTech Co. (347850) has net assets worth ₩63.92 Billion KRW as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩88.53 Billion) and total liabilities (₩24.61 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩63.92 Billion |
| % of Total Assets | 72.21% |
| Annual Growth Rate | 172.34% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 171.93 |
D&D PharmaTech Co. - Net Assets Trend (2022–2024)
This chart illustrates how D&D PharmaTech Co.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for D&D PharmaTech Co. (2022–2024)
The table below shows the annual net assets of D&D PharmaTech Co. from 2022 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩70.11 Billion | +50.30% |
| 2023-12-31 | ₩46.65 Billion | +394.16% |
| 2022-12-31 | ₩9.44 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to D&D PharmaTech Co.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1575122645000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩5.28 Billion | 7.54% |
| Other Components | ₩374.19 Billion | 533.70% |
| Total Equity | ₩70.11 Billion | 100.00% |
D&D PharmaTech Co. Competitors by Market Cap
The table below lists competitors of D&D PharmaTech Co. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shenzhen Tatfook Tech
SHE:300134
|
$484.05 Million |
|
Postal Realty Trust Inc
NYSE:PSTL
|
$484.08 Million |
|
Hanjin Kal
KO:18064K
|
$484.09 Million |
|
MegaChips Corporation
F:MHC
|
$484.13 Million |
|
Jiangsu Longda Superalloy Co. Ltd. A
SHG:688231
|
$483.97 Million |
|
Dogus Otomotiv Servis ve Ticaret AS
IS:DOAS
|
$483.73 Million |
|
Anhui Huilong Agricultural Means of Production Co Ltd
SHE:002556
|
$483.73 Million |
|
Hyperion Metals Limited
PINK:TAOFF
|
$483.72 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in D&D PharmaTech Co.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 46,649,608,090 to 70,112,118,580, a change of 23,462,510,490 (50.3%).
- Net loss of 28,622,601,560 reduced equity.
- Share repurchases of 37,980,495,020 reduced equity.
- Other factors increased equity by 90,065,607,070.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-28.62 Billion | -40.82% |
| Share Repurchases | ₩37.98 Billion | -54.17% |
| Other Changes | ₩90.07 Billion | +128.46% |
| Total Change | ₩- | 50.30% |
Book Value vs Market Value Analysis
This analysis compares D&D PharmaTech Co.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 12.59x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 92.25x to 12.59x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | ₩905.17 | ₩83500.00 | x |
| 2023-12-31 | ₩4472.97 | ₩83500.00 | x |
| 2024-12-31 | ₩6634.34 | ₩83500.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently D&D PharmaTech Co. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -40.82%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -250.27%
- • Asset Turnover: 0.12x
- • Equity Multiplier: 1.39x
- Recent ROE (-40.82%) is above the historical average (-491.25%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -1441.35% | -22285.31% | 0.01x | 9.92x | ₩-137.01 Billion |
| 2023 | 8.43% | 21.06% | 0.24x | 1.70x | ₩-731.16 Million |
| 2024 | -40.82% | -250.27% | 0.12x | 1.39x | ₩-35.63 Billion |
Industry Comparison
This section compares D&D PharmaTech Co.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,689,906,881
- Average return on equity (ROE) among peers: -10.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| D&D PharmaTech Co. (347850) | ₩63.92 Billion | -1441.35% | 0.38x | $484.01 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |